Orsus

Orsus Therapeutics is a biotechnology company dedicated to developing next-generation cell therapies for the treatment of solid tumors. The company leverages a proprietary platform to engineer "logic-gated" CAR-T cells designed to improve specificity and reduce off-target toxicities, a major hurdle in treating solid cancers. Founded by industry veterans and backed by leading venture capital firms, Orsus aims to expand the reach of immunotherapy beyond hematological malignancies. Their approach focuses on enhancing the safety and efficacy of adoptive T-cell transfers through sophisticated genetic engineering and synthetic biology.